Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients

Reumatol Clin. 2021 Jan;17(1):57-58. doi: 10.1016/j.reuma.2018.12.004. Epub 2019 Jan 28.
[Article in En, Spanish]
No abstract available

Publication types

  • Letter